Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
CNBC Television · 6:14
China is moving fast in biotech, but Goldman Sachs analyst Salveen Richter says its output is still mostly "me-too betters" and re-engineered known targets. She expects novel innovation to follow, and that Western pha...